Sign In
6 Jan 2015 07:00
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Board Appointment
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Gracielle Anna Maria Beijerbacht-Schutjens to the Board as an Executive Director with immediate effect.
Gracielle, aged 48, has over 18 years of clinical development experience. After completing her studies in health education and biology, she progressed through the clinical research industry from a clinical research associate to starting her own contract research organisation in 2001, which was subsequently acquired by Venn Life Sciences B.V. (a subsidiary of the Company) in 2010. Having worked with a broad range of pharmaceutical, biotechnology and medical device companies, Gracielle has managed clinical trials across multiple sites with extensive investigator relationships throughout the Benelux region and is a member of a number of professional research associations.
Commenting on the appointment, Venn CEO, Tony Richardson, said: "We are very pleased to welcome Gracielle to the Board as an Executive Director. Gracielle's experience of multi-site clinical trials and relationships will be a benefit to Venn as we continue to execute our strategy of becoming a leading mid-sized CRO in Europe."
Additional information:
Gracielle is currently a director of G.A.M. Schutjens Holding B.V. and Venn Life Sciences B.V., formerly Uptoyou B.V., a CRO business acquired by Venn in March 2010. She has not held any other directorships in the past 5 years.
Save as set out in this announcement there are no further matters to be disclosed under Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.
Enquiries:
Venn Life Sciences Holdings Plc | www.vennlifesciences.com |
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 |
Orla Mc Guinness, Marketing Manager | Tel: +353 153 73 269 |
|
|
Zeus Capital (Nominated Adviser and Broker) |
|
Andrew Jones / Ross Andrews | Tel: +44 (0)161 831 1512 |
Dominic Wilson | Tel: +44 (0)20 7533 7727 |
|
|
Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or venn@walbrookpr.com |
Paul McManus | Mob: +44 (0)7980 541 893 |
Lianne Cawthorne | Mob: +44 (0)7584 391 303 |
About Venn Life Sciences Limited:
Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.
Follow the stocks
